RT Journal Article
SR Electronic
A1 Butterman, Eric
T1 TMC435 Effective in the Treatment of HCV Genotype 1 Infection
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 12
SP 14
OP 14
DO 10.1177/155989771112009
UL http://mdc.sagepub.com/content/11/12/14.abstract
AB Both the PILLAR [TMC435-C205; NCT00882908] and ASPIRE [TMC435-C206; NCT00980330] trials demonstrated that TMC435 (an oral inhibitor of the hepatitis C virus NS3/4A protease) administered once-daily with pegylated interferon alpha-2a (PegIFNa-2a) and ribavirin (RBV) is safe, has potent antiviral activity, and shortens total treatment by 24 weeks compared with PegIFNa-2a/RBV alone.